Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025
Liquidia Corporation (NASDAQ: LQDA), un'azienda biofarmaceutica specializzata in terapie per malattie cardiopolmonari rare, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per giovedì 8 maggio 2025. La società terrà una webcast alle 8:30 a.m. ora orientale per discutere i risultati finanziari e fornire un aggiornamento aziendale. Gli investitori potranno accedere alla webcast tramite il sito web di Liquidia, e la registrazione sarà disponibile in archivio per un anno.
Liquidia Corporation (NASDAQ: LQDA), una compañía biofarmacéutica centrada en terapias para enfermedades cardiopulmonares raras, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el jueves 8 de mayo de 2025. La empresa realizará una transmisión en línea a las 8:30 a.m., hora del Este para discutir los resultados financieros y ofrecer una actualización corporativa. Los inversores podrán acceder a la transmisión a través del sitio web de Liquidia, y la grabación estará archivada durante un año.
Liquidia Corporation (NASDAQ: LQDA)는 희귀 심폐 질환 치료제에 중점을 둔 생명공학 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 8일 목요일로 예정했습니다. 회사는 동부 표준시 기준 오전 8시 30분에 웹캐스트를 진행하여 재무 실적을 논의하고 회사 업데이트를 제공할 예정입니다. 투자자들은 Liquidia 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 녹화본은 1년간 보관됩니다.
Liquidia Corporation (NASDAQ : LQDA), une société biopharmaceutique spécialisée dans les thérapies des maladies cardiopulmonaires rares, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le jeudi 8 mai 2025. La société tiendra une webdiffusion à 8h30, heure de l'Est pour discuter des résultats financiers et fournir une mise à jour d'entreprise. Les investisseurs pourront accéder à la webdiffusion via le site web de Liquidia, et un enregistrement sera archivé pendant un an.
Liquidia Corporation (NASDAQ: LQDA), ein biopharmazeutisches Unternehmen, das sich auf Therapien für seltene kardiopulmonale Erkrankungen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Donnerstag, den 8. Mai 2025 geplant. Das Unternehmen wird um 8:30 Uhr Eastern Time eine Webkonferenz abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können über die Website von Liquidia auf die Webkonferenz zugreifen, und eine Aufzeichnung wird für ein Jahr archiviert.
- None.
- None.
MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When will Liquidia (LQDA) report Q1 2025 earnings?
What time is Liquidia's Q1 2025 earnings call?
How can I access Liquidia's Q1 2025 earnings webcast?
How long will Liquidia's Q1 2025 earnings webcast recording be available?
